Fig. 4

OCTA imaging of a mixed type 1, type 2 MNV before treatment and after 25 months of follow-up that regressed with 5 injections of anti-VEGF. a–c Baseline OCTA imaging from the RTVue XR Avanti device. a En face image from the choriocapillaris revealing the MNV network. Green arrow demarcates an example of a mature vessel. b Corresponding B-scan through the lesion revealing sub-RPE and subretinal (yellow arrow) flow. c Corresponding B-scan through the lesion showing choriocapillaris segmentation lines and hypertransmission in areas of atrophy. d–f Endpoint OCTA imaging from the Cirrus HD-OCT 5000 device. d En face image from the choriocapillaris without clear MNV boundaries identified but prominent choroidal vasculature visible. Cyan line denotes the cross-sectional location through which the B-scan was derived. e Corresponding B-scan through the center of the image with flow signal showing RPE loss, hypertransmission due to atrophy that now extends to the foveal center, and no aberrant flow signal attributable to MNV. f Corresponding B-scan through the center of the image showing choriocapillaris segmentation lines